Introduction
============

Hearing loss was found around 1--3 of 1,000 newborns [@B1][@B2][@B3][@B4], however in high risk group, the increasing of 10--20 folds was observed[@B1][@B2]. In Thailand, one study performed universal hearing screening in newborns, they found that hearing loss was occurred about 1.7 per 1,000 newborns[@B5]. Hearing loss in infants caused delay speech and language development, social and emotional problems, and educational failure [@B6][@B7][@B8][@B9][@B10][@B11]. Therefore, early detection of hearing in newborns as soon as possible will lead to early intervention. Particularly in the first 6 months of age, early intervention can help patients and caregivers on the improvement of quality of life, and can reduce the incidence of hearing loss handicap[@B12][@B13][@B14][@B15][@B16][@B17][@B18].

The Joint Committee on Infant Hearing (JCIH)[@B3] recommended universal newborn hearing screening programs to identify all children with significant bilateral hearing loss (30--40 dB or more in the speech range frequency approximately 500--4,000 Hz) up until 3 months of age. Then, treatments or interventions to improve patients\' hearing should be started instantly at 6 months of age[@B2][@B4][@B19][@B20][@B21]. Currently, universal hearing loss screening program has not been implemented in Thailand. This might due to limited health care personnel and financial support.

The standard of newborn hearing loss screening is otoacoustic emission (OAE) with auditory brainstem response (ABR)[@B12]. However, this approaches need instruments and cannot apply in some setting with limited resources especially in low-and-middle income countries (LMICs), e.g., some primary care settings in Thailand. JCIH (2000) suggested that all newborns age 1 to 28 days should be screened using the following 5 risk factors[@B15]; (1) family history of hereditary childhood sensorineural hearing loss, (2) in utero infection: cytomegalovirus, rubella, syphilis, herpes, or toxoplasmosis, (3) craniofacial anomalies, including those with morphological abnormalities of the pinna and ear canal excluding isolated ear pits and tags, (4) admitted to the neonatal intensive care unit (NICU) more than 48 hours or on mechanical ventilation for at least five days, and (5) stigmata or other findings associated with a syndromes associated with congenital hearing loss. In addition, the risk factors of 2007 JCIH[@B12] has changed as the following; NICU care of more than 5 days or any of the following regardless of length of stay: extracorporeal membrane oxygenation, assisted ventilation, exposure to ototoxic medications (gentamycin and tobramycin) or loop diuretics (furosemide), and hyperbilirubinemia that requires exchange transfusion.

However, risk factors screening had never evaluated the worth of early diagnosis and the capability of factors for prevention permanent hearing loss. Furthermore, JCIH risk factor provided the sense of equal point, but in fact it was unequal. Each risk factor has different effect to hearing loss probability. As a results, this study aimed to develop a simple screening score to predict hearing loss, and to serve primary care settings as a screening tool for newborns hearing loss.

Materials and methods
=====================

1. Study population and data collection
---------------------------------------

The details of study design, study population, and inclusion/exclusion criteria were showed and published elsewhere[@B22]. Briefly, data were collated from 3 tertiary hospital located in Northern part of Thailand including Uttaradit Hospital, Budhachinaraj Hospital and Sawanpracharuk Hospital. All newborns who passed the three steps of hearing test were included. The 3-step procedures were transitory evoked OAEs (TEOAEs) (AccuScreen GN Otometrics, PATH medical GmbH, Germering, Germany) followed by automated ABR (AABR) examination (Madsen AccuScreen Otometrics, PATH medical GmbH, Germering, Germany) in case of failed to TEOAE testing. Then children who had deviant AABR results were sent to otolaryngologist for final evaluation with conventional ABR (Sentiero Advanced Otometrics, Germany). ABR more than 25-dB normalized hearing level was considered as hearing loss. Patients were excluded if they did not allowed by parents to participate the study, loss-to-follow up, and die before discharge from the hospital.

Patients\' characteristics and all relevant parameters were collected as presented previously[@B22]. For example, maternal diseases, family history of congenital sensorineural hearing loss, maternal age, Apgar score at 5 minutes, birth weight, intrauterine infection (maternal infection in uterus with cytomegalovirus, rubella, syphilis, herpes, or toxoplasmosis), craniofacial anomalies, mechanical ventilator use, meningitis, sepsis, ototoxic exposure, delivery route, hyperbilirubinemia. All these factors were used as criteria for infant hearing loss which already mentioned previously[@B12][@B15].

2. Statistical analysis
-----------------------

Standard score was defined as JCIH definition which already stated in introduction part. Derived score was determined using multivariable Poisson risk regression. Only variables which reached statistical significance (*P*\<0.05) were included in the final evaluation. Each variable was weighted by an incident risk ratio coefficient, and transformed to an item score by dividing each regression coefficient with the smallest coefficient in the model and rounding the number to its nearest integer[@B23][@B24]. Cutoff points were determined by statistical significance and the results of the receiver operating characteristic (ROC) curve value. Classical diagnostic values; i.e., specificity, sensitivity, positive predictive value, negative predictive value, likelihood ratio (positive/negative), were computed using a standard method[@B25][@B26]. All *P* values are 2-tailed and considered statistically significant when the value is less than 0.05. Analyses were performed using STATA ver. 11.0 (StataCorp LP, College Station, TX, USA).

3. Ethics approval
------------------

The study was approved by Chiang Mai University Hospital, Uttaradit Hospital, Budhachinaraj Hospital, and Swanpracharuk Hospital Ethical Committee for Clinical Research. All caregivers received all information about the study, and signed an informed consent sheet before participation.

Results
=======

Patients\' characteristics were illustrated previously[@B22]. Briefly, there was a total of 3,120 infants which 1,534 infants (49%) were male, and 1,586 infants (51%) were female.

Univariable analysis of standard hearing loss screening risk factors found that all factors showed statistical significant ([Table 1](#T1){ref-type="table"}).

After univariable analysis, multivariable analysis using backward stepwise Poisson regression was performed. There were 5 variables remained in the model to construct a screening scoring system. The screening scoring system for hearing loss is the summation of each point from the following factors; Craniofacial anomaly (yes=4, no= 0), Ototoxicity (yes=9, no=0), Birth weight (low birth weight=1, normal=0), family history (Relative) of congenital sensorineural hearing loss (yes=4, no=0), and Apgar score (abnormal=6.5, normal=0) ([Table 2](#T2){ref-type="table"}). With this scoring system, the score illustrated a very good performance for hearing loss prediction (area under the ROC \[AuROC\], 0.95; 95% CI, 0.93--0.97) ([Fig. 1](#F1){ref-type="fig"}). To make an easy way to use and remember, we named this tool as 'COBRA' score which derived from initial of each factor.

Performances of diagnostic capability of the screening model compare with standard tool preferred by JCIH were reported in [Table 3](#T3){ref-type="table"}. Comparing with standard score, COBRA score showed similar results in all diagnostic indices. With this scoring system, the score discriminated patients with hearing loss from those without hearing loos with well validity (AuROC 84%, 88%, 86% for cutoff point at 4, 6, and 8 respectively) ([Table 3](#T3){ref-type="table"}).

Discussion
==========

Our study showed that the clinical risk scoring scheme can be used as a screening tool to identify subjects for hearing loss. This score, which we named the "COBRA score", distinguished the presence or absence of hearing loss in newborns. To our best knowledge, this study is the first clinical score for screening of hearing loss in newborns in Thailand, an Asian countries and one of the LMICs.

In this study, we found 5 clinical risk factors can predict hearing loss in newborns. There were Craniofacial anomaly, Ototoxicity, Birth weight, family history (Relative) of congenital sensorineural hearing loss, and Apgar score. Our finding was similar to those in the previous study in Belgium[@B27] that factors included in the model were family history of hearing loss, low birth weight, low Apgar score. In addition, a study in Thailand[@B19] also showed the similar results to ours that craniofacial anomalies, low birth weight, ototoxic drugs use, are the risk factors of newborns hearing loss. Another one study also used similar four predictors (prematurity, 5-minute Apgar score ≤6, intracranial complication, and craniofacial abnormality) to screen hearing loss in newborns, and showed that the benefit of the screening might motivate parents to follow up with diagnostic ABR testing so that early identification can lead to early intervention[@B28]. Although these studies used risk factors for hearing loss screening in newborns, they did not weighted each factor as we did. Lieu et al.[@B28] categorized patients into 3 groups based-on numbers of risk factors. However, since we knew that each risk factor influent the risk of hearing loss as an unequal point, thus counting with the same weight might lead to classification bias.

Considering diagnostic performances of this COBRA score, all diagnostic indices showed a good performance and showed similar results with standard tool of JCIH. Therefore, this COBRA score can be used as newborns screening tool particularly in primary setting where the instruments are scarce.

Strengths of our study should be highlighted. First, we used data from real-world practice, thus this reflect the real situation and can be used in the setting with similar circumstances. Second, we included a number of patients which large enough to capture all related clinical characters. In addition, large sample provided statistical power to diminish random error and bias. Third, this a prospective cohort study, thus data were collected prospectively. This means that information bias, reviewer bias and patient selection bias can be minimized. Forth, the score contains only five clinical parameters which easy to remember as 'COBRA,' without additional cost of laboratory testing.

The limitations of this study is that data were collected from only 3 hospitals, thus the findings may not be generalizable to all entries country. However in setting with similar health system, this tool can be applied. Another limitation is external validity. Since this study only develop the score but not validation, thus further validation in other population should be investigated before implementation.

Despite limitation, the simple screening tool (COBRA score) containing five clinical factors for hearing loss in newborns in primary care setting were developed and evaluated. In addition, derived score was also comparable with standard tool currently applied in clinical practice. The medical person in primary care setting can use this screening model for evaluate the hearing of newborn. If the result of screening score was more than 4 points, parents were motivated to bring the children for follow-up with diagnostic ABR testing so that early detection can lead to early intervention.
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###### Risk factors for hearing loss in study subjects (n=3,120)

![](kjped-60-353-i001)

  Variable                                                      Auditory brainstem response at 3 months   *P* value      
  ------------------------------------------------------------- ----------------------------------------- -------------- ---------
  Intrauterine infection                                                                                                 
   No                                                           130 (96.3)                                2981 (99.9)    \<0.001
   Yes                                                          5 (3.7)                                   4 (0.1)        
  Family history of congenital sensorineural hearing loss                                                                
   No                                                           122 (90.4)                                2,985 (100)    \<0.001
   Yes                                                          13 (9.6)                                  0 (0)          
  Birth weight (g)                                                                                                       
   ≤2,500                                                       36 (26.7)                                 381 (12.8)     \<0.001
   \>2,500                                                      99 (73.3)                                 2,604 (87.2)   
  Apgar score in 5 min                                                                                                   
   Normal (\>6)                                                 64 (47.4)                                 2,909 (97.5)   \<0.001
   Abnormal (≤6)                                                71 (52.6)                                 76 (2.5)       
  Craniofacial anomalies                                                                                                 
   No                                                           105 (77.8)                                2,964 (99.3)   \<0.001
   Yes                                                          30 (22.2)                                 21 (0.7)       
  Use of breathing machine \>5 days                                                                                      
   No                                                           65 (48.1)                                 2,927 (98.1)   \<0.001
   Yes                                                          70 (51.9)                                 58 (1.9)       
  Meningitis                                                                                                             
   No                                                           120 (88.9)                                2,983 (99.9)   \<0.001
   Yes                                                          15 (11.1)                                 2 (0.1)        
  Ototoxic exposure^\*^                                                                                                  
   No                                                           58 (43.0)                                 2,899 (97.1)   \<0.001
   Yes                                                          77 (57.0)                                 86 (2.9)       
  Severe hyperbilirubinemia (term≥18 mg/dL, preterm≥15 mg/dL)                                                            
   No                                                           92 (68.1)                                 2,964 (99.3)   \<0.001
   Yes                                                          43 (31.9)                                 21 (0.7)       
  No. of risk factors                                                                                                    
   0                                                            48 (35.6)                                 2,913 (97.6)   \<0.001
   1                                                            57 (42.2)                                 62 (2.1)       
   2                                                            29 (21.5)                                 9 (0.3)        
   3                                                            1 (0.7)                                   1 (0.03)       

Values are presented as number (%).

^\*^Ototoxic medications (gentamycin and tobramycin).

###### Derived scores (COBRA) from multivariable Poisson risk regression (n=3,120)
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  Variable                                                             Beta-coefficient   *P* value   Item score   Assigned score
  -------------------------------------------------------------------- ------------------ ----------- ------------ ----------------
  Craniofacial anomaly                                                                                             
   No                                                                  \-                 \-          \-           0
   Yes                                                                 0.954              \<0.001     3.80         4
  Ototoxicity^\*^                                                                                                  
   No                                                                  \-                 \-          \-           0
   Yes                                                                 2.249              \<0.001     8.95         9
  Birth weight (g)                                                                                                 
   Normal (\>2,500)                                                    \-                 \-          \-           0
   Low birth weight (≤2,500)                                           0.251              0.278       1.00         1
  Family history (Relative) of congenital sensorineural hearing loss                                               
   No                                                                  \-                 \-          \-           0
   Yes                                                                 1.071              0.001       4.26         4
  Apgar score                                                                                                      
   Normal (\>6)                                                        \-                 \-          \-           0
   Abnormal (≤6)                                                       1.667              \<0.001     6.63         6.5

^\*^Ototoxic medications (gentamycin and tobramycin).

COBRA, Craniofacial anomaly, Ototoxicity, Birth weight, family history (Relative) of congenital sensorineural hearing loss, and Apgar score.

###### Diagnostic values of standard scores and derived scores
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  Diagnostic value       Standard score         Derived score cutoff point                          
  ---------------------- ---------------------- ---------------------------- ---------------------- ----------------------
  Sensitivity (95% CI)   64.4 (62.8--66.1)      85.44 (84.20--86.67)         81.55 (80.19--82.91)   75.73 (74.22--77.23)
  Specificity (95% CI)   97.6 (97.0--98.1)      83.39 (82.09--84.70)         95.53 (94.80--96.25)   96.69 (96.06--97.31)
  PPV (95% CI)           54.7 (53.0--56.5)      14.94 (13.69--16.19)         38.36 (36.65--40.06)   43.82 (42.08--45.56)
  NPV (95% CI)           98.4 (97.9--98.8)      99.41 (99.14--99.68)         99.35 (99.06--99.63)   99.15 (98.83--99.47)
  AuROC                  0.81                   0.84                         0.88                   0.86
  LHR+ (95% CI)          26.72 (20.59--34.66)   25.21 (14.69--43.26)         58.52 (36.26--94.44)   51.56 (33.74--78.82)

CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; AuROC, area under the receiver operating characteristics; LHR+, likelihood ratio of positive.
